$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

사상자 추출물이 DNCB로 유도된 BALB/c 마우스의 접촉성 피부염에 미치는 효과

Effects of Torilis japonica Extract on DNCB-induced Contact Dermatitis in BALB/c Mice

韓方眼耳鼻咽喉皮膚科學會誌 = The journal of Korean Medicine Ophthalmology & Otolaryngology & Dermatology, v.29 no.4, 2016년, pp.61 - 77  

이규영 (상지대학교 한의과대학 안이비인후피부과학교실) ,  송은혜 (상지대학교 한의과대학 약리학교실) ,  홍철희 (상지대학교 한의과대학 안이비인후피부과학교실)

초록
AI-Helper 아이콘AI-Helper

목적: 본 연구에서는 TJ 열수추출물이 아토피 피부염에 미치는 효과를 확인하고자 하였다. 방법: 2, 4-dinitrochlorobenzen (DNCB)으로 BALB/c 마우스에 1차 감작 후 3주간 2차 감작을 시행하여 아토피 유사 피부병변을 나타내는 접촉성 피부염을 유발한 뒤 동결건조 처리된 TJ 분말을 (PBS/EtOH/Cremophor=6:1:3)에 용해시켜 쥐의 등 피부에 10, 50 mg/ml 농도로 3주간 도포하였다. 결과: TJ 열수추출물은 아토피 피부 병변의 염증세포 침윤을 억제하였고 (10, 50 mg/ml ) 표피와 진피 두께를 회복시켰으며 (10, 50 mg/ml ), 혈청에서 히스타민 방출을 억제하였다 (00 mg/ml ). 또한 Th2 세포와 관련된 cytokine인 interleukin (IL)-4, IL-5, IL-13과 thymic stromal lymphopoietin (TSLP)의 mRNA 발현 양을 감소시켰고 (10, 50 mg/ml ), Th2 chemokine인 thymus- and activation-regulated chemokine (TARC or CCL17)의 mRNA의 발현 양을 감소시켰다 (10, 50 mg/ml ). 결론: TJ 열수추출물을 BALB/c 마우스에 외용하였을 때 항아토피 효과가 있음을 확인하였으며 따라서 TJ가 아토피 피부염 치료의 외용제로 활용될 수 있을 것으로 사료된다.

주제어

참고문헌 (71)

  1. Kimber L, Basketter DA, Gerberick GF, Dearman RJ. Allergic contact dermatitis. International immunopharmacology. 2002;2(2-3):201-11. 

  2. Sung YY, Yang WK, Lee AY, Kim DS, Nho KJ, Kim YS, et al. Topical application of an ethanol extract prepared from illicium verum suppresses atopic dermatitis in NC/Nga mice. J Ethnopharmacol. 2012;144:151-9. 

  3. Takeda K, Gelfand EW. Mouse models of allergic diseases. Curr Opin Immunol. 2009;21:660-5. 

  4. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. The Journal of clinical investigation. 2004;113(5):651-7. 

  5. Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003;361(9352):151-60. 

  6. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Annals of nutrition & metabolism. 2015;66 suppl 1:8-16. 

  7. Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunological reviews. 2011;242(1):233-46. 

  8. Wang IJ, Guo YL, Weng HJ, Hsieh WS, Chuang YL, Lin SJ, et al. Environmental risk factors for early infantile atopic dermatitis. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2007;18(5):441-7. 

  9. Hijnen D, De Bruin-Weller M, Oosting B, Lebre C, De Jong E, Bruijnzeel-Koomen C, et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cellattracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. The Journal of allergy and clinical immunology. 2004;113(2):334-40. 

  10. Sher A, Coffman RL. Regulation of immunity to parasites by T cells and T cell-derived cytokines. Annual review of immunology. 1992;10:385-409. 

  11. Romagnani S. Immunologic influences on allergy and the TH1/TH2 balance. The Journal of allergy and clinical immunology. 2004;113(3):395-400. 

  12. Akdis CA, Akdis M, Simon D, Dibbert B, Weber M, Gratzl S, et al. T cells and T cell-derived cytokines as pathogenic factors in the nonallergic form of atopic dermatitis. The Journal of investigative dermatology. 1999;113(4):628-34. 

  13. Hasbold J, Hong JS, Kehry MR, Hodgkin PD. Integrating signals from IFN-gamma and IL-4 by B cells: positive and negative effects on CD40 ligand-induced proliferation, survival, and division-linked isotype switching to IgG1, IgE and IgG2a. Journal of immunology. 1999;163(8):4175-81. 

  14. Izuhara K, Shirakawa T. Signal transduction via the interleukin-4 receptor and its correlation with atopy. International journal of molecular medicine. 1999;3(1):3-10. 

  15. Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nature medicine. 2012;18(5):693-704. 

  16. Urb M, Sheppard DC. The role of mast cells in the defence against pathogens. PLoS pathogens. 2012;8(4):e1002619. 

  17. Weller K, Foitzik K, Paus R, Syska W, Maurer M. Mast cells are required for normal healing of skin wounds in mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2006;20(13):2366-8. 

  18. Amin K. The role of mast cells in allergic inflammation. Respiratory medicine. 2012;106(1):9-14. 

  19. Kouro T, Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. International immunology. 2009;21(12):1303-9. 

  20. Simon D, Braathen LR, Simon HU. Eosinophils and atopic dermatitis. Allergy. 2004;59(6):561-70. 

  21. Onoue A, Kabashima K, Kobayashi M, Mori T, Tokura Y. Induction of eosinophil- and Th2-attracting epidermal chemokines and cutaneous late-phase reaction in tape-stripped skin. Experimental dermatology. 2009;18(12):1036-43. 

  22. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nature immunology. 2002;3(7):673-80. 

  23. Takai T, Chen X, Xie Y, Vu AT, Le TA, Kinoshita H, et al. TSLP expression induced via Toll-like receptor pathways in human keratinocytes. Methods in enzymology. 2014;535:371-87. 

  24. Yoo J, Omori M, Gyarmati D, Zhou B, Aye T, Brewer A, et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. The Journal of experimental medicine. 2005;202(4):541-9. 

  25. Correale CE, Walker C, Murphy L, Craig TJ. Atopic dermatitis: a review of diagnosis and treatment. American family physician. 1999;60(4):1191-8, 1209-10. 

  26. Herman SM, Vender RB. Antihistamines in the treatment of dermatitis. Journal of cutaneous medicine and surgery. 2003;7(6):467-73. 

  27. Stanbury RM, Graham EM. Systemic corticosteroid therapy--side effects and their management. The British journal of ophthalmology. 1998;82(6):704-8. 

  28. Segal AO, Ellis AK, Kim HL. CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology. 2013;9(1):24. 

  29. Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatric drugs. 2013;15(4):303-10. 

  30. Kim GT, Lee SH, Kim YM. Torilis japonica extract, a new potential EMT suppressor agent by regulation of EGFR signaling pathways. International journal of oncology. 2014;45(4):1673-9. 

  31. Kim SM, Kim TH, Lee EB. Anti-inflammatory activities of Torilis japonica fruit. The Korean Society of Pharmacognosy. 1998;29(4):384-90. 

  32. Kim MS, Lee YM, Moon EJ, Kim SE, Lee JJ, Kim KW. Anti-angiogenic activity of torilin, a sesquiterpene compound isolated from Torilis japonica. International journal of cancer. 2000;87(2):269-75. 

  33. Kim MS, Baek JH, Park MT, Sohn TK, Kim SE, Lee JJ, et al. Anti-invasive activity of torilin, a sesquiterpene compound isolated from Torilis japonica. Oncology reports. 2001;8(2):359-64. 

  34. Cho WI, Choi JB, Lee K, Chung MS, Pyun YR. Antimicrobial activity of torilin isolated from Torilis japonica fruit against Bacillus subtilis. Journal of food science. 2008;73(2):37-46. 

  35. Sone K, Yamamoto-Sawamura T, Kuwahara S, Nishijima K, Ohno T, Aoyama H, et al. Changes of estrous cycles with aging in female F344/n rats. Experimental animals / Japanese Association for Laboratory Animal Science. 2007;56(2):139-48. 

  36. Park SJ, Lee HA, Kim JW, Lee BS, Kim EJ. Platycodon grandiflorus alleviates DNCBinduced atopy-like dermatitis in NC/Nga mice. Indian journal of pharmacology. 2012;44(4):469-74. 

  37. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454(7203):445-54. 

  38. Petersen LJ, Mosbech H, Skov PS. Allergen-induced histamine release in intact human skin in vivo assessed by skin microdialysis technique: characterization of factors influencing histamine releasability. The Journal of allergy and clinical immunology. 1996;97(2):672-9. 

  39. Gschwandtner M, Mildner M, Mlitz V, Gruber F, Eckhart L, Werfel T, et al. Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model. Allergy. 2013;68(1):37-47. 

  40. Minami K, Kamei C. A chronic model for evaluating the itching associated with allergic conjunctivitis in rats. International immunopharmacology. 2004;4(1):101-8. 

  41. Guttman-Yassky E, Dhingra N, Leung DY. New era of biologic therapeutics in atopic dermatitis. Expert opinion on biological therapy. 2013;13(4):549-61. 

  42. Hamelmann E, Gelfand EW. IL-5-induced airway eosinophilia--the key to asthma? Immunological reviews. 2001;179:182-91. 

  43. Corren J. Anti-interleukin-5 antibody therapy in asthma and allergies. Current opinion in allergy and clinical immunology. 2011;11(6):565-70. 

  44. Oh MH, Oh SY, Yu J, Myers AC, Leonard WJ, Liu YJ, et al. IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin. Journal of immunology. 2011;186(12):7232-42. 

  45. Stein ML, Villanueva JM, Buckmeier BK, Yamada Y, Filipovich AH, Assa'ad AH, et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. The Journal of allergy and clinical immunology. 2008;121(6):1473-83. 

  46. Gittler JK, Kreuger JG, Guttman-Yassky E. Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis. J Allergy Clin Immunol. 2013;131:300-13. 

  47. Jung M, Lee TH, Oh HJ, Kim H, Son Y, Lee EH, et al. Inhibitory effect of 5,6-dihydroergosteol- glucoside on atopic dermatitis-like skin lesions via suppression of NF-kappaB and STAT activation. Journal of dermatological science. 2015;79(3):252-61. 

  48. Kabashima K. New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity. Journal of dermatological science. 2013;70(1):3-11. 

  49. Fonacier LS, Dreskin SC, Leung DY. Allergic skin diseases. The Journal of allergy and clinical immunology. 2010;125(2 Suppl 2):S138-49. 

  50. Liu FT, Goodarzi H, Chen HY. IgE, mast cells, and eosinophils in atopic dermatitis. Clinical reviews in allergy & immunology. 2011;41(3):298-310. 

  51. Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nature immunology. 2008;9(11):1215-23. 

  52. Lindstedt KA, Kovanen PT. Isolation of mast cell granules. Current protocols in cell biology. 2006;Chapter 3(Unit 3):16. 

  53. Greaves MW. Antihistamines in dermatology. Skin pharmacology and physiology. 2005;18(5):220-9. 

  54. Imaizumi A, Kawakami T, Murakami F, Soma Y, Mizoguchi M. Effective treatment of pruritus in atopic dermatitis using H1 antihistamines (second-generation antihistamines): changes in blood histamine and tryptase levels. Journal of dermatological science. 2003;33(1):23-9. 

  55. Tazawa T, Sugiura H, Sugiura Y, Uehara M. Relative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis. Archives of dermatological research. 2004;295(11):459-64. 

  56. Yamazaki F, Aragane Y, Maeda A, Matsushita K, Ueno K, Yudate T, et al. Overactivation of IL-4-induced activator protein-1 in atopic dermatitis. Journal of dermatological science. 2002;28(3):227-33. 

  57. Ackerman SJ, Bochner BS. Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunology and allergy clinics of North America. 2007;27(3):357-75. 

  58. Corren J. Inhibition of interleukin-5 for the treatment of eosinophilic diseases. Discovery medicine. 2012;13(71):305-12. 

  59. Hamid Q, Naseer T, Minshall EM, Song YL, Boguniewicz M, Leung DY. In vivo expression of IL-12 and IL-13 in atopic dermatitis. The Journal of allergy and clinical immunology. 1996;98(1):225-31. 

  60. Wang YH, Liu YJ. Thymic stromal lymphopoietin, OX40-ligand, and interleukin-25 in allergic responses. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2009;39(6):798-806. 

  61. Moran TP, Vickery BP. The Epithelial Cell-Derived Atopic Dermatitis Cytokine TSLP Activates Neurons to Induce Itch. Pediatrics. 2014;134 suppl 3:S160-1. 

  62. Alysandratos KD, Angelidou A, Vasiadi M, Zhang B, Kalogeromitros D, Katsarou-Katsari A, et al. Increased affected skin gene expression and serum levels of thymic stromal lymphopoietin in atopic dermatitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2010;105(5):403-4. 

  63. Vestergaard C, Yoneyama H, Murai M, Nakamura K, Tamaki K, Terashima Y, et al. Overproduction of Th2-specific chemokines in NC/Nga mice exhibiting atopic dermatitis-like lesions. The Journal of clinical investigation. 1999;104(8):1097-1105. 

  64. Saeki H, Tamaki K. Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases. Journal of dermatological science. 2006;43(2):75-84. 

  65. Shimada Y, Takehara K, Sato S. Both Th2 and Th1 chemokines (TARC/CCL17, MDC/CCL22, and Mig/CXCL9) are elevated in sera from patients with atopic dermatitis. Journal of dermatological science. 2004;34(3):201-8. 

  66. Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, et al. Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activationregulated chemokine level is closely related with disease activity. The Journal of allergy and clinical immunology. 2001;107(3):535-41. 

  67. College of Oriental Medicine Compilation Committee of Herbalogy. Herbalogy. Seoul:Younglimsa. 2006:630-1. 

  68. Park SM. The documentary examining of gynecologic symptoms and medical substances of fumigation treatment. Master's Thesis Kyung-San University. 2002:57. 

  69. Sin MG. Clinical Herbalogy. Younglimsa. 1994:197, 271, 590. 

  70. Koo BS, Hwang EI, So SH, Lee SK, Han GH, Kim NM. Effect of Torilis Fructus on Procollagen Biosynthesis and Activity of Matrix Metalloproteinase-I(MMP-1) in Human Dermal Fibroblast. Kor. J. Pharmacogn. 2007;38(4):350. 

  71. Choi JE, Park BK, Jin MR. Anti-inflammatory and Antioxidant Effects of Water Extracts of Sasangja-tang(SSJ) and Gami-sasangja-tang (GSJ). Collection of dissertations Institute of Oriental Medicine Daejeon University. 2015;23(2):7-8. 

저자의 다른 논문 :

섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트